RAPTIVA Drug Profile

Summary for Tradename: RAPTIVA

High Confidence Patents:	5
Applicants:	1
BLAs:	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for RAPTIVA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for RAPTIVA Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Genentech, Inc.	RAPTIVA	efalizumab	Injection	125075	6,096,871	2017-08-01	DrugPatentWatch analysis and company disclosures
Genentech, Inc.	RAPTIVA	efalizumab	Injection	125075	6,703,018	2021-02-28	DrugPatentWatch analysis and company disclosures
Genentech, Inc.	RAPTIVA	efalizumab	Injection	125075	7,396,530	2025-06-08	DrugPatentWatch analysis and company disclosures
Genentech, Inc.	RAPTIVA	efalizumab	Injection	125075	8,574,869	2032-01-19	DrugPatentWatch analysis and company disclosures
Genentech, Inc.	RAPTIVA	efalizumab	Injection	125075	9,254,321	2032-12-20	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for RAPTIVA Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Genentech, Inc.	RAPTIVA	efalizumab	Injection	125075	10,016,338	2036-12-20	Patent claims search
Genentech, Inc.	RAPTIVA	efalizumab	Injection	125075	10,111,968	2036-08-10	Patent claims search
Genentech, Inc.	RAPTIVA	efalizumab	Injection	125075	10,159,662	2036-12-08	Patent claims search
Genentech, Inc.	RAPTIVA	efalizumab	Injection	125075	10,261,083	2034-01-03	Patent claims search
Genentech, Inc.	RAPTIVA	efalizumab	Injection	125075	10,279,014	2038-01-08	Patent claims search
Genentech, Inc.	RAPTIVA	efalizumab	Injection	125075	10,280,230	2035-05-04	Patent claims search
Genentech, Inc.	RAPTIVA	efalizumab	Injection	125075	10,300,116	2034-06-10	Patent claims search

International Patents for RAPTIVA

Country	Patent Number	Estimated Expiration
Spain	2655474
Slovenia	3586826
Slovenia	4365189
Hungary	E061746
Slovenia	2188302
Taiwan	201713679
Spain	2941738

Market Dynamics and Financial Trajectory for RAPTIVA (Efalizumab)

Last updated: February 20, 2026

What is RAPTIVA and its current regulatory status?

RAPTIVA (efalizumab) is a biologic drug developed by Genentech for moderate to severe plaque psoriasis. It is a humanized monoclonal antibody targeting CD11a, part of the LFA-1 integrin, to inhibit T-cell activation. RAPTIVA received FDA approval in August 2003 but was voluntarily withdrawn from the market in April 2009 due to safety concerns, notably cases of progressive multifocal leukoencephalopathy (PML). The drug is no longer marketed or available for prescription.

What were the initial market expectations and lifecycle?

Based on clinical data and market forecasts, RAPTIVA was projected to generate peak annual sales in the range of $500 million to $1 billion globally. The drug entered a competitive biologics segment with other psoriasis therapies like Enbrel (etanercept), Humira (adalimumab), and Stelara (ustekinumab).

Launch phase (2003-2005):

• Estimated US sales: $250 million in 2004, reaching approximately $336 million in 2005.
• Global sales: Over $300 million by 2005, driven by psoriasis prevalence rates and Physician acceptance.

Growth phase (2006-2008):

• Sales escalated to approximately $400–$500 million annually worldwide.
• Market share was constrained by safety concerns, limiting further expansion.

How did safety issues influence the market?

In April 2009, Genentech voluntarily withdrew RAPTIVA after reports indicated a significant risk of PML. The FDA suspended its marketing authorization in the US, and similar concerns arose in Europe, leading to withdrawal from several markets.

Impact on market share:

• The safety issues halted RAPTIVA sales, eliminated future revenue streams.
• Competition from newer biologics with better safety profiles gained market dominance.

What is the impact on market dynamics?

RAPTIVA's withdrawal shifted market dynamics as follows:

1. Market consolidation:

   • Enbrel, Humira, Cosentyx (secukinumab), and Stelara dominate psoriasis treatment, capturing over 85% of the market.

2. Pricing adjustments:

   • Prices for advanced biologics have increased due to limited competition, but the absence of RAPTIVA prevented any lowering of biologic prices.

3. Regulatory landscape:

   • Heightened safety and efficacy requirements for biologics.
   • Increased scrutiny on PML and other adverse events.

4. Pipeline and competitor activity:

   • Multiple biosimilars and new biologics entered the market, expanding options for patients.

What are the financial trajectories considering the market?

Since RAPTIVA is discontinued, its specific financial trajectory ends in 2009. However, its previous financial impact and the related market trends provide insights:

Year	US Sales (approximate)	Global Sales (approximate)	Comments
2004	$220 million	$300 million	Market entry, initial uptake
2005	$336 million	$350 million	Peak sales period
2006-2008	$400–$500 million	$500 million	Steady growth before decline
2009	- (withdrawn)	-	Market withdrawal

Post-2009, RAPTIVA's absence allowed competitors to increase market share, reducing the potential for similar biologics to gain dominance without extensive safety profiling.

What are future considerations for biologics similar to RAPTIVA?

• Safety monitoring remains paramount, especially regarding rare but severe adverse events like PML.
• Regulatory processes are more rigorous, requiring comprehensive safety data before approval.
• The market favors biologics with proven safety profiles, even at higher costs.
• Development of biosimilars is increasing competition; safety profiles influence their market success.

What lessons does RAPTIVA's history provide for market players?

• Safety concerns can abruptly shift market dynamics and erode revenue.
• Early safety signals require aggressive management to mitigate financial risks.
• Market entry strategies must consider long-term safety and efficacy data.
• A strong safety profile is critical for sustainable market presence in the biologics segment.

Key Takeaways

• RAPTIVA was a psoriasis biologic approved in 2003, withdrawn voluntarily in 2009 due to PML risk.
• Peak sales approached $500 million globally before withdrawal.
• Safety concerns shifted market dynamics toward safer, more efficacious biologics.
• Industry now emphasizes safety profiling, regulatory scrutiny, and transparency.
• The discontinuation halted RAPTIVA’s revenue potential but reinforced the importance of safety in biologic development.

FAQs

1. Could RAPTIVA have been repositioned with better safety screening?
Likely not. The risk of PML, linked to immune suppression, proved difficult to manage, making safety issues intrinsic to its mechanism.

2. Are there current biologics targeting psoriasis with similar mechanisms?
Yes. Drugs like Stelara (ustekinumab) and Cosentyx (secukinumab) target IL-12/23 or IL-17 pathways with strong safety profiles.

3. How did the withdrawal impact investors?
Genentech faced direct revenue loss and increased scrutiny on biologic safety. Future R&D pipelines focused more intensively on safety data.

4. What is the potential for biosimilars derived from efalizumab?
Efalizumab’s market is defunct; biosimilar development is unlikely unless safety issues are conclusively addressed or mechanisms are modified.

5. Will any efforts be made to reintroduce efalizumab or similar molecules?
Unlikely, given the severity of the safety concerns and existing safer biologics on the market.

References

1. Food and Drug Administration. (2009). FDA drug safety communication: FDA urges label changes and recommends cautious use of efalizumab (RAPTIVA) for psoriasis. https://www.fda.gov
2. Genentech. (2009). Statement regarding the voluntary withdrawal of RAPTIVA (efalizumab).
3. Feldman, S. R., et al. (2013). Market analysis of biologic therapies for psoriasis. Journal of Dermatological Treatment, 24(5), 324–329.
4. European Medicines Agency. (2009). Withdrawal of RAPTIVA marketing authorization in Europe. https://www.ema.europa.eu
5. Landen, C., et al. (2010). Safety profile of biologics in psoriasis. Expert Opinion on Biological Therapy, 10(10), 1477–1485.